期刊
JOURNAL OF CLINICAL ONCOLOGY
卷 26, 期 4, 页码 633-638出版社
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2008.14.0095
关键词
-
类别
资金
- NCI NIH HHS [CA98543] Funding Source: Medline
Purpose To compare three-drug chemotherapy with cisplatin, doxorubicin, and methotrexate with four-drug chemotherapy with cisplatin, doxorubicin, methotrexate, and ifosfamide for the treatment of osteosarcoma. To determine whether the addition of muramyl tripeptide ( MTP) to chemotherapy enhances event-free survival ( EFS) and overall survival in newly diagnosed patients with osteosarcoma. Patients and Methods Six hundred sixty-two patients with osteosarcoma without clinically detectable metastatic disease and whose disease was considered resectable received one of four prospectively randomized treatments. All patients received identical cumulative doses of cisplatin, doxorubicin, and methotrexate and underwent definitive surgical resection of primary tumor. Patients were randomly assigned to receive or not to receive ifosfamide and/or MTP in a 2 x 2 factorial design. The primary end points for analysis were EFS and overall survival. Results In the current analysis, there was no evidence of interaction, and we were able to examine each intervention separately. The chemotherapy regimens resulted in similar EFS and overall survival. There was a trend toward better EFS with the addition of MTP ( P =.08). The addition of MTP to chemotherapy improved 6-year overall survival from 70% to 78% ( P =.03). The hazard ratio for overall survival with the addition of MTP was 0.71 ( 95% CI, 0.52 to 0.96). Conclusion The addition of ifosfamide to cisplatin, doxorubicin, and methotrexate did not enhance EFS or overall survival for patients with osteosarcoma. The addition of MTP to chemotherapy resulted in a statistically significant improvement in overall survival and a trend toward better EFS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据